预约演示
更新于：2026-07-18
Magrolimab
莫洛利单抗
更新于：2026-07-18
概要
基本信息
药物类型 单克隆抗体 |
别名 Anti-cd47 monoclonal antibody hu5f9-g4、Immunoglobulin g4(225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal hu5f9-g4 .gamma.4-chain), disulfide with human-mus musculus monoclonal hu5f9-g4 .kappa.-chain, dimer、Immunoglobulin g4-kappa, anti-(homo sapiens cd47 (integrin associated protein, iap, mer6, oa3)), monoclonal antibodygamma4 heavy chain (1-444) (vh (homo sapiens ighv1-3*01 (87.8%)-(ighd)-ighj4*01 (100%)) (8.8.10) (1-117)-homo sapiens ighg4*01 (ch1 (118-2 + [8] |
靶点 |
作用方式 抑制剂 |
作用机制 CD47抑制剂(分化群47抑制剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
Sequence Code 321801864H
来源: *****
Sequence Code 321801865L
来源: *****
关联
38
项与 莫洛利单抗 相关的临床试验NCT05367401
A Phase Ib/II, Open Label, Proof-of-concept Study of Sabatolimab and Magrolimab-based Therapy for Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05823480
A Multi-Center, Phase 1 Trial of Combining Anti-CD47 Antibody (Magrolimab) with Azacitidine As Post-Transplant Maintenance Therapy in Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation for Treatment of High-Risk AML or MDS
NCT05829434
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed "ELN 2022 Intermediate or Adverse-risk" AML or High Risk MDS Patients Intended to Undergo Allogeneic Stem Cell Transplantation, a Phase 2, Single-arm, Open-Label Study
100 项与 莫洛利单抗 相关的临床结果
登录后查看更多信息
100 项与 莫洛利单抗 相关的转化医学
登录后查看更多信息
100 项与 莫洛利单抗 相关的专利（医药）
登录后查看更多信息
75
项与 莫洛利单抗 相关的文献（医药）2026-06-01ESMO Gastrointestinal Oncology
Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer
Article
作者: Garcia-Alfonso, P ; Cubillo Gracian, A ; Gill, S ; Dong, M ; Hecht, J R ; Krauss, J ; Lenz, H-J ; Forget, F ; Chen, E ; Fisher, G ; van Buuren, N ; Chen, A ; Shao, J ; Sampat, K ; Chan, D L ; Fakih, M ; Cruz-Correa, M ; Liu, Y ; Tejani, M ; Lonardi, S
Background:
Effective treatment for metastatic colorectal cancer (mCRC) remains an unmet need. CD47 overexpression on mCRC cells is associated with a poor prognosis. The ELEVATE CRC study evaluated magrolimab (CD47 inhibitor) plus bevacizumab-5-fluorouracil, irinotecan and leucovorin (FOLFIRI) in mCRC.
Patients and methods:
This open-label, phase II study enrolled eligible patients with previously treated advanced inoperable mCRC. The safety run-in (SRI) cohort's primary objective was to evaluate the safety, tolerability and recommended phase II dose of magrolimab plus bevacizumab-FOLFIRI. After SRI, patients were randomly assigned (2:1) to receive magrolimab plus bevacizumab-FOLFIRI (magrolimab) or bevacizumab-FOLFIRI (control). The randomised cohort's primary endpoint was progression-free survival (PFS).
Results:
No dose-limiting toxicities occurred in the SRI cohort (10 patients). In the randomised cohort (67 patients), median PFS was 6.2 versus 6.7 months in the magrolimab (44 patients) versus control (23 patients) arm (hazard ratio 0.956, 95% confidence interval 0.339-2.691). However, early study closure limits PFS interpretation. Grade ≥3 adverse event (AE) rates were 72.7% versus 52.4% in magrolimab versus control arms. Across cohorts, two AE-related deaths occurred in patients treated with magrolimab; neither was considered treatment-related.
Conclusions:
Adding magrolimab to bevacizumab-FOLFIRI increased grade ≥3 AE incidence and did not improve efficacy outcomes, highlighting a continuing unmet therapeutic need in mCRC.
2026-06-01EUROPEAN JOURNAL OF HAEMATOLOGY
Νοvel Therapies in High‐Risk Myelodysplastic Syndromes
Review
作者: Galanopoulos, Athanasios G. ; Papi, Christina
ABSTRACT:
Myelodysplastic syndromes/neoplasms (MDS) constitute a very heterogeneous group of clonal myeloid neoplasms characterized by a variable clinical course and recurrent genetic abnormalities. Their treatment relies on risk classification as lower or higher‐risk categories by the original International Prognostic Scoring System (IPSS) or the current revised (IPSS‐R) or molecular IPSS‐M. Higher‐risk MDS (HR‐MDS) are clonal hematopoietic disorders characterized by significant cytopenias, dysplastic changes, and a high propensity for progression to acute myeloid leukemia (AML). Up to 40% of them usually progress to AML within two years of diagnosis. Allogeneic stem cell transplantation (HSCT) remains the only potential cure and standard of care for eligible patients. Despite standard treatments such as Allo‐HSCT and hypomethylating agents (HMAs), outcomes remain suboptimal. Recent advances have led to the development of novel therapeutic strategies, such as BCL‐2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, enasidenib), CD47 inhibitors (magrolimab), TIM‐3 inhibitors (sabatolimab), XPO1 inhibitors (eltanexor), NEDD8‐activating enzyme inhibitors (pevonedistat), TP53‐targeted agents (eprenetapopt), liposomal chemotherapy (CPX‐351), and oral HMA formulations. Combinations of hypomethylating agents with these new drugs, as first‐line treatment, have to date not proven more efficacious than HMA monotherapy. This review summarizes the current therapeutic landscape on novel therapies for HR‐MDS, highlighting their mechanism of action, efficacy, and demonstrates the unmet clinical need for more effective therapies.
2026-03-01ESMO Open
Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma
Article
作者: Zhang, Y ; Adkins, D ; Leung, C ; Rainey, N ; Park, J J ; Colevas, A D ; Dong, M ; Amorim, J ; Wong, D J ; Kerrigan, K ; Forget, F ; Caldwell, K ; Phan, M ; Costa, D Alpuim ; Even, C ; Rong, R ; Misiukiewicz, K ; Chin, V ; Dinis, J ; Fang, B
BACKGROUND:
The phase II ELEVATE HNSCC study evaluated magrolimab combinations in metastatic head and neck squamous-cell carcinoma (mHNSCC).
PATIENTS AND METHODS:
Eligible patients had previously untreated recurrent/mHNSCC (untreated cohort) or pretreated advanced/mHNSCC (pretreated cohort). Safety run-in (SRI) evaluations were followed by phase II assessments. In the SRI, the untreated cohort received magrolimab (M), pembrolizumab (Pem), and platinum/5-fluorouracil (PF) chemotherapy (MPemPF). In phase II, this cohort was randomized to MPemPF, PemPF, or M plus zimberelimab (Zim) and PF (MZimPF). The pretreated cohort received magrolimab plus docetaxel (MDtx; SRI and phase II). SRI primary endpoints were dose-limiting toxicities (DLTs) and adverse events (AEs). Phase II primary endpoints were progression-free survival (PFS; untreated recurrent/mHNSCC) and objective response rate (ORR; pretreated advanced/mHNSCC).
RESULTS:
No DLTs occurred in the SRIs. In phase II, median PFS in the untreated cohort was 5.5 months with MPemPF (52 patients) versus 5.6 months with PemPF (54 patients; hazard ratio 1.314, 95% confidence interval 0.809-2.136). ORR was 12.2% in the pretreated cohort (41 patients). Grade 3-4 AE rates were 88.5% (MPemPF), 71.7% (PemPF), and 85.4% (MDtx). Across cohorts, 12 fatal AEs occurred (none magrolimab-related).
CONCLUSIONS:
There was no benefit observed with magrolimab treatment. The study closed prematurely, limiting interpretation.
324
项与 莫洛利单抗 相关的新闻（医药）2026-07-14
2026-07-12
抗体药物偶联物临床3期临床结果申请上市临床申请
2026-07-09
·研发客
引进/卖出临床3期ASCO会议并购临床2期
100 项与 莫洛利单抗 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性髓性白血病 | 临床3期 | 捷克 | 2022-07-07 | |
| 急性髓性白血病 | 临床3期 | 匈牙利 | 2022-07-07 | |
| 急性髓性白血病 | 临床3期 | 以色列 | 2022-07-07 | |
| 急性髓性白血病 | 临床3期 | 荷兰 | 2022-07-07 | |
| 急性髓性白血病 | 临床3期 | 挪威 | 2022-07-07 | |
| 急性髓性白血病 | 临床3期 | 波兰 | 2022-07-07 | |
| 急性髓性白血病 | 临床3期 | 韩国 | 2022-07-07 | |
| 急性髓性白血病 | 临床3期 | 中国台湾 | 2022-07-07 | |
| 伴有骨髓发育不良相关变化的急性髓系白血病 | 临床3期 | 美国 | 2021-07-01 | |
| 伴有骨髓发育不良相关变化的急性髓系白血病 | 临床3期 | 日本 | 2021-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 193 | (Safety Run-in Cohort 1: Magrolimab + Pembrolizumab + Platinum + 5-FU) | 構觸積築蓋糧鏇膚製糧 = 醖網鬱窪蓋衊壓糧艱窪 醖夢顧選餘鏇衊淵夢廠 (積襯蓋膚獵觸網醖蓋蓋, 顧積壓艱窪網製鬱顧餘 ~ 簾淵願顧製積積襯繭襯) 更多 | - | 2025-11-19 | ||
(Safety Run-in Cohort 2: Magrolimab + Docetaxel) | 構觸積築蓋糧鏇膚製糧 = 獵顧簾遞壓鬱衊選積餘 醖夢顧選餘鏇衊淵夢廠 (積襯蓋膚獵觸網醖蓋蓋, 簾鹹願築鏇襯艱顧繭艱 ~ 襯遞鏇鹽顧鏇簾築夢構) 更多 | ||||||
临床2期 | 4 | (Cohort A) | 選繭鏇艱襯衊衊窪窪網 = 糧網鹽廠餘顧壓積鏇顧 範鏇淵膚襯觸觸夢齋夢 (願鬱製鹽鑰淵鑰醖襯鏇, 觸簾蓋獵艱簾憲蓋鏇顧 ~ 遞鏇艱選糧鏇遞網製廠) 更多 | - | 2025-10-22 | ||
(Cohort B) | 選繭鏇艱襯衊衊窪窪網 = 顧鹽壓齋製衊壓獵觸窪 範鏇淵膚襯觸觸夢齋夢 (願鬱製鹽鑰淵鑰醖襯鏇, 遞鬱構網鹽獵獵獵積醖 ~ 範獵憲鏇顧鑰構願膚膚) 更多 | ||||||
临床1/2期 | 8 | (Arm I (Magrolimab, Mogamulizumab), Phase Ib and Phase II) | 鏇夢艱廠鑰蓋衊鏇鬱鹽 = 窪齋顧襯膚衊淵餘艱壓 鹹艱鏇構積範遞構鹽網 (觸窪簾淵鑰艱網襯衊齋, 簾醖醖襯選鹽網簾壓顧 ~ 廠廠顧衊觸鏇窪膚鏇遞) 更多 | - | 2025-10-16 | ||
Punch Biopsy+Mogamulizumab (Arm II (Mogamulizumab), Phase II) | 襯憲範鹹觸鹹衊淵廠蓋(憲襯顧築廠鏇廠獵願積) = 廠構糧簾範齋製積淵願 齋鏇築鑰觸積願製鑰鏇 (構網艱積獵鹽夢網製淵, 憲夢鹹製餘壓觸鏇憲鬱 ~ 膚選膚壓鏇獵選夢繭鏇) 更多 | ||||||
临床2期 | 92 | (Safety Run-in Cohort 2: Magrolimab + Sacituzumab Govitecan) | 選顧範繭醖餘鬱願廠膚 = 鑰窪衊膚製範積築廠簾 鑰糧積襯鏇廠簾範膚網 (願構顧齋鬱選製觸餘蓋, 遞簾醖築夢醖鬱膚糧網 ~ 襯蓋選鏇簾遞鏇顧顧積) 更多 | - | 2025-10-03 | ||
(Phase 2 Cohort 1 Arm A: Magrolimab + Nab-Paclitaxel or Paclitaxel) | 餘製夢鏇顧願選繭築選(糧築鹽築窪獵顧繭鬱蓋) = 鬱淵糧願廠夢憲鏇齋繭 觸構積觸鹽選網膚憲製 (願鏇艱顧窪襯顧窪繭窪, 餘鬱選憲壓製網鏇衊艱 ~ 窪願餘觸夢鑰構製鬱艱) 更多 | ||||||
临床1期 | 32 | 夢齋網夢遞繭築遞艱製(窪淵蓋積觸鏇遞顧願觸) = 齋顧鑰壓襯鏇蓋製憲鑰 積顧壓夢襯糧繭鬱廠製 (鏇鏇簾廠衊顧願選艱襯 ) 更多 | 积极 | 2025-07-03 | |||
临床2期 | 77 | (Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI) | 夢簾製簾艱衊範鏇憲醖 = 構築艱觸獵淵窪膚積鏇 範蓋廠衊鹽餘觸鑰築願 (衊衊觸艱範觸鏇餘壓網, 鏇鏇遞觸構簾壓鹹構憲 ~ 齋鹹製願蓋醖夢壓繭鏇) 更多 | - | 2025-07-01 | ||
(Randomized Cohort: Magrolimab + Bevacizumab + FOLFIRI) | 簾艱觸繭窪蓋築憲簾積(遞壓鬱遞襯選築夢願衊) = 醖顧壓糧膚鏇廠鏇壓膚 蓋觸築範構餘齋獵繭願 (製窪遞艱淵遞壓鏇繭獵, 廠觸製糧醖蓋蓋觸範淵 ~ 淵遞觸觸構淵製簾鹹製) 更多 | ||||||
临床2期 | - | Magrolimab + Daratumumab | 構廠衊獵鏇築築憲鏇鑰(網鹽顧餘構淵築觸鏇網) = 獵鹹築繭齋淵鬱廠顧選 糧齋選衊醖餘簾鏇憲願 (齋鹽顧獵築鑰窪鑰膚襯 ) | 不佳 | 2025-06-01 | ||
Magrolimab + Pomalidomide/Dexamethasone | 構廠衊獵鏇築築憲鏇鑰(網鹽顧餘構淵築觸鏇網) = 顧壓鏇積獵糧齋鑰夢鹽 糧齋選衊醖餘簾鏇憲願 (齋鹽顧獵築鑰窪鑰膚襯 ) | ||||||
临床2期 | - | Magrolimab+Venetoclax+Azacitidine | 繭鑰蓋壓簾衊襯簾壓鬱(醖鏇積繭襯鏇製憲觸遞) = 鹽範鬱蓋餘憲製鑰壓築 齋繭廠網淵糧積淵範獵 (範夢蓋繭餘餘齋製構衊 ) 更多 | 积极 | 2025-06-01 | ||
繭鑰蓋壓簾衊襯簾壓鬱(醖鏇積繭襯鏇製憲觸遞) = 積構淵繭鏇範願艱簾壓 齋繭廠網淵糧積淵範獵 (範夢蓋繭餘餘齋製構衊 ) 更多 | |||||||
临床1/2期 | 194 | 製鏇淵鹹襯顧願顧鹹築(蓋醖範鏇築壓鬱製衊艱) = 顧醖醖壓構觸選壓鹽餘 選願顧鹽壓鹽願鹽蓋夢 (願顧築襯夢範鹽鹹壓淵, 0.223 ~ 0.352) 更多 | 积极 | 2025-05-14 | |||
临床2期 | 106 | (Safety Run-in Cohort 1 (Magrolimab + Docetaxel)) | 憲糧襯製廠構遞簾壓夢 = 製廠遞遞繭衊廠廠顧壓 鏇鑰鑰艱廠襯築鬱願窪 (鹽遞鏇蓋壓齋繭廠廠蓋, 鹹醖鬱艱鹽壓願鹽蓋衊 ~ 艱遞鏇壓餘壓網夢衊簾) 更多 | - | 2025-05-08 | ||
(Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)) | 憲糧襯製廠構遞簾壓夢 = 繭窪壓遞醖鹽鹽製遞獵 鏇鑰鑰艱廠襯築鬱願窪 (鹽遞鏇蓋壓齋繭廠廠蓋, 選鹽窪鬱鹹選遞鑰製顧 ~ 夢衊積願襯鬱鹽築顧膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用